Immunology and Vaccine Development Program The Immunology and Vaccine Development (IVD) Program bring together researchers and clinicians engaged in the study of cancer immunobiology, basic immunology, immunotherapy, vaccinology, and infectious diseases who shared a vision of developing immunologic strategies that could be deployed to harness the immune system for targeting malignancies as well as infectious diseases that develop and progress in immuno-compromised individuals. Modulating the immune system with vaccines for the prevention of human infections has had many very dramatic successes, but the paradigms and strategies for reagent development to prevent diseases such as polio or diphtheria have proven neither adequate nor readily translatable to infections such as HIV and tuberculosis or to the treatment of cancer. The IVD program strengthens existing collaborative interactions, provides opportunities for new collaborations, and promotes a synergy of research efforts that will accelerate progress in cancer immunology, immuno-therapeutics, and cancer vaccine development. The program's 50 members, 96% of whom have peer-reviewed funding, are drawn from all three partners institutions, three schools and 16 departments. The program has $16.8M in peer reviewed funding, including $4.8M from the NCI (direct dollars.) Program members are highly productive and collaborative, with 994 peer-reviewed publications during this grant period, of which 22% were intra-programmatic, 26% were inter-programmatic and 22% were inter-institutional. The program's specific aims are to: 1. Develop a greater breadth of cellular therapy interventional clinical trials, including initiating trials to advance cellular therapy to become an approved standard therapy for leukemia and solid tumors. 2. Define the immunological obstacles in the host and tumor microenvironment that interfere with effective immunotherapeutic targeting of tumors so that strategies can be developed to effectively treat cancers not currently responsive to therapy. 3. Identify, test, and validate improved strategies for infection control in immune compromised cancer patients. 4. Adapt and translate insights from our basic, preclinical, and clinical studies in vaccine biology to enhance immune responses to cancer antigens and improve the efficacy of adoptive T cell transfer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Career Development (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Fred Hutchinson Cancer Research Center
United States
Zip Code
Holly, Mayumi K; Smith, Jason G (2018) Adenovirus infection of human enteroids reveals interferon sensitivity and preferential infection of goblet cells. J Virol :
Cheng, Heather H (2018) The resounding effect of DNA repair deficiency in prostate cancer. Urol Oncol 36:385-388
Poudel, Kumud R; Roh-Johnson, Minna; Su, Allen et al. (2018) Competition between TIAM1 and Membranes Balances Endophilin A3 Activity in Cancer Metastasis. Dev Cell 45:738-752.e6
Eaton, Keith D; Romine, Perrin E; Goodman, Gary E et al. (2018) Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility. J Thorac Oncol 13:649-659
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313
Gauthier, Jordan; Turtle, Cameron J (2018) Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Curr Res Transl Med 66:50-52
Graves, Scott S; Parker, Maura H; Stone, Diane et al. (2018) Anti-Inducible Costimulator Monoclonal Antibody Treatment of Canine Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:50-54
Méndez, Eduardo; Rodriguez, Cristina P; Kao, Michael C et al. (2018) A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 24:2740-2748
Amundsen, Susan K; Smith, Gerald R (2018) The RecB helicase-nuclease tether mediates Chi hotspot control of RecBCD enzyme. Nucleic Acids Res :
Montgomery, Elizabeth T; Noguchi, Lisa M; Dai, James Y et al. (2018) Acceptability of and Adherence to an Antiretroviral-Based Vaginal Microbicide among Pregnant Women in the United States. AIDS Behav 22:402-411

Showing the most recent 10 out of 1267 publications